What question did this study set out to answer?

To assess the cost-effectiveness of Nivolumab plus AVD compared to Brentuximab vedotin plus AVD in treating advanced-stage classical Hodgkin lymphoma.

May 21, 2026ClinicoEconomics and Outcomes Research0 citationsOpen Access

Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis

BLBiao LiSun Yat-sen University JYJingjing YangSun Yat-sen University JLJing LiTongji University

Key Points

To assess the cost-effectiveness of Nivolumab plus AVD compared to Brentuximab vedotin plus AVD in treating advanced-stage classical Hodgkin lymphoma.
Conducted a cost-effectiveness analysis using a Markov model based on the S1826 trial (n=970).
Estimated total direct costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICER).
Performed sensitivity analyses to assess the robustness of the findings.
Nivolumab-AVD yielded 6.560 QALYs and 15.659 LYs, surpassing Brentuximab vedotin-AVD by 0.504 QALYs and 0.551 LYs.
Total costs were $784,839 for Nivolumab-AVD versus $789,205 for Brentuximab vedotin-AVD.
Nivolumab-AVD demonstrated negative ICERs (-$8,656 per QALY; -$7,926 per LY), indicating it was dominant with lower costs and better health outcomes.

Abstract

Objective: To evaluate the cost-effectiveness of nivolumab plus doxorubicin/vinblastine/dacarbazine (N-AVD) versus brentuximab vedotin-AVD (BV-AVD) as first-line treatment for advanced-stage classical Hodgkin lymphoma. Design: Cost-effectiveness analysis using a Markov model based on the S1826 trial (n=970). We estimated total direct costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICER). Sensitivity analyses assessed robustness. Results: Nivolumab-AVD yielded 6. 560 QALYs and 15. 659 LYs, representing gains of 0. 504 QALYs and 0. 551 LYs over Brentuximab vedotin-AVD. Total costs were 784, 839 for Nivolumab-AVD compared with 789, 205 for Brentuximab vedotin-AVD. Nivolumab-AVD was associated with negative incremental cost-effectiveness ratios (-8, 656 per QALY; -7, 926 per LY) and was dominant, offering superior health outcomes at a lower overall cost. Conclusion: From a Chinese healthcare payer perspective, nivolumab-AVD is more cost-effective than brentuximab vedotin-AVD for advanced-stage classical Hodgkin lymphoma, offering lower costs and better health outcomes. Keywords: classical Hodgkin Lymphoma, nivolumab-AVD, brentuximab vedotin-AVD, quality-adjusted life-years, incremental cost-effectiveness ratio

问 AI

Bookmark

View Full Paper